{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-229101","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.770066+00:00","generated_at":"2026-06-10T23:28:01.309724+00:00","sec_items":["1.01","2.03","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Appoints Charles S. Ryan as President; subsidiary issues up to $1M promissory note to EryDel S.p.A.","bullets":["Promissory note of up to $1.0M to EryDel S.p.A. in two tranches: $500k at 5.07% per annum; second $500k at AFR.","Maturity July 1, 2024; obligations discharged upon closing of Stock Purchase Agreement or termination in certain circumstances.","Charles S. Ryan, Ph.D. appointed President, effective Sept 1, 2023; previously President/CEO of Travecta Therapeutics, CEO of Neurotrope.","Compensation: $500k base salary, up to 40% bonus, option for 545,000 shares vesting over 4 years.","Severance: 12-month salary on qualifying termination; 18-month salary if change of control, plus equity acceleration and health benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-229101","json":"https://secwatch.observer/filing/0001193125-23-229101.json","markdown":"https://secwatch.observer/filing/0001193125-23-229101.md","text":"https://secwatch.observer/filing/0001193125-23-229101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/d437171d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:28:01.309724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d038c4236c99a2978ff9001de1009694ee0eb8b2","claim":"Quince Therapeutics, Inc. incurred loan of up to $1.0 million with Erydel S.p.A. at 5.07% per annum maturing July 1, 2024.","evidence_excerpt":"shares (società per azioni) incorporated under the laws of Italy (“EryDel”) (the “Promissory Note”), pursuant to which EryDel Italy promised to make advances to EryDel of up to $1.0 million. The Company previously entered into a Stock Purchase Agreement, dated as of July 21, 2023, by and among the Company, EryDel, and the other parties thereto. Under the terms of","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $1.0 million"},{"label":"Counterparty","value":"Erydel S.p.A."},{"label":"Rate","value":"5.07% per annum"},{"label":"Maturity","value":"July 1, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"983a378968","claim":"Charles S. Ryan was appointed as President at Quince Therapeutics, Inc..","evidence_excerpt":"On August 30, 2023, the Board of Directors of the Company approved the appointment of Charles S. Ryan, Ph.D., as the President of the Company, effective as of September 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312523229101/0001193125-23-229101-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}